Sample size determination for bioequivalence assessment using a multiplicative model.

D Hauschke; V W Steinijans; E Diletti; M Burke

doi:10.1007/bf01061471

Home/Archive/PubMed

PubMed · 1287202

Sample size determination for bioequivalence assessment using a multiplicative model.

D Hauschke·V W Steinijans·E Diletti·M Burke

View original source ↗Export metadata ↓

Abstract

In bioequivalence studies Cmax and AUC serve as the primary pharmacokinetic characteristics of rate and extent of absorption. Based on pharmacokinetic relationships and on empirical evidence, the distribution of these characteristics corresponds to a multiplicative model, which implies a logarithmic normal distribution in the case of a parametric analysis. Hence, consideration is given to exact and approximate formulas of sample sizes in the case of a multiplicative model.

Explore related subjects

Methods Models, Biological Pharmacokinetics Therapeutic Equivalency Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

D Hauschke, V W Steinijans, E Diletti, M Burke. 1992. Sample size determination for bioequivalence assessment using a multiplicative model.. https://doi.org/10.1007/bf01061471

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

New methods presented in statistical journals.

Explore the source record for details and available documents.

Methods↗

PubMed2004

An efficient route to thioglycosides with the 2,3-anhydro-D-ribo stereochemistry.

An improved route for the synthesis of p-tolyl 2,3-anhydro-5-O-benzoyl-1-thio-beta-D-ribofuranoside and its alpha anomer, which are important intermediates in the synthesis of alpha- and beta-D-arabinofuranosides, has been developed. The products are obtained in six steps from D-xylose in 39% overall yield.

Methods↗

PubMed2004

Clinical pharmacokinetic data of racemic drugs obtained by the indirect method following precolumn diastereomer formation: is the influence of racemization during chiral derivatization significant?

This report reviews the stereoselective data of a number of racemic drugs (n = 17) obtained from indirect chiral method (via diastereomer formation) in comparison to similar data generated by the application of a direct chiral method. While it was noted that the indirect method still continued to be used to characterize the stereoselective disposition of racemic drugs, the present review critically evaluates the issue of racemization that has the potential to skew the stereoselective data obtained from the indirect method. The review describes various remedies to counter and/or minimize the impact of racemization on the final outcome of the stereoselective analysis by the indirect method. On the basis of this review it could be concluded that the indirect method is a viable and important tool for gathering stereoselective data of racemic drugs used in medical practice as well for those racemic drugs still in discovery and developmental stages.

Methods↗